Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CRNX
CRINETICS PHARMACEUTICALS, INC.
NASDAQ
$84.84
▼ DOWN 0.01% (-0.01)

KEY STATISTICS

Market Cap$8.99 B
52w High$84.89
52w Low$31.00
Dividend Yield—
Frequency—
P/E-16.83
Volume711.48K
Shares Out.105.97M

COMPANY

LEADERSHIP

R. Scott Struthers
CHIEF EXECUTIVE
R. Scott Struthers

COMPENSATION 2026

Salary$718,500
Stock Awards$3,280,540
Incentive Plan Pay$462,355
All Other Comp.$7,000
Total$11,628,959

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 18, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
594

PRICE TARGET

Target High$85.00
Target Low$84.00
Target Median$85.00
Target Consensus$84.86

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$21.04M
NOV
5
THU

PRICE

$84.84 ▼ DOWN 0.01% (−$0.01)
$84.85$84.86$84.879:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM84.84

About Crinetics Pharmaceuticals, Inc.

https://www.crinetics.com ↗

Crinetics Pharmaceuticals is a clinical-stage biotech developing oral therapeutics for rare endocrine diseases, with lead candidate Paltusotine in late-stage trials for acromegaly and other compounds in early trials.

INDUSTRY

Biotechnology

A PRODUCT CRINETICS PHARMACEUTICALS, INC. IS KNOWN FOR

PALSONIFY™ (paltusotine)
PALSONIFY™ (paltusotine)

PALSONIFY™ is the first FDA-approved once-daily oral medication for acromegaly in adults, offering a significant advancement over injectable treatments, and is also under investigation for carcinoid syndrome associated with neuroendocrine tumors.

COMPETITORS

COMPETITOR
ASND COMPARE
BBIO COMPARE
IONS COMPARE
NVS COMPARE
PFE COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q1-2026Q2-2026
Product— $10.31M $24.04M ▲
License$14M — —
License and Service— $428K $1.08M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
149
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.01% · 3.4M
XSU.TO
0.27% · 2.6M
SCHA
0.18% · 501.0K
XPH
3.51% · 243.0K
FESM
0.28% · 217.8K
DFAC
0.02% · 135.5K
SBIO
4.57% · 129.9K
NUSC
0.58% · 97.2K
XRS2.DE
0.28% · 94.2K
MNA
2.09% · 63.0K
PRFZ
0.15% · 51.1K
RSSL
0.28% · 49.5K
FNY
0.70% · 49.1K
JHSC
0.35% · 30.4K
BBSC
0.34% · 29.9K
BKMC
0.20% · 15.4K
MNTL
3.54% · 13.1K
ETLZ.DE
0.32% · 8.6K
PILL
2.36% · 6.8K
GSSC
0.04% · 4.8K
MRGR
2.33% · 4.4K
ACSG
0.67% · 4.1K
STXK
0.39% · 4.0K
RFLR
0.29% · 3.2K
ESSC
0.61% · 2.7K
PQ
PQSG
0.23% · 1.7K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
81.04%
HOLDERS
364
TOP 12 OF 364 · RANKED BY POSITION SIZE
Fmr LLC
15.8M sh · $592.74M
Blackrock, Inc.
9.8M sh · $365.18M
Vanguard Group Inc
9.2M sh · $381.94M
Farallon Capital Management LLC
9.0M sh · $336.37M
Wellington Management Group Llp
8.4M sh · $349.11M
Driehaus Capital Management LLC
6.5M sh · $269.96M
Blackrock Inc.
6.2M sh · $279.06M
Price T Rowe Associates Inc /Md/
6.2M sh · $232.48M
Janus Henderson Group Plc
4.5M sh · $164.23M
Ecor1 Capital, LLC
4.3M sh · $155.74M
Bellevue Group AG
3.3M sh · $119.13M
Geode Capital Management, LLC
2.7M sh · $102.09M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Josh Gottheimer
Josh Gottheimer
Purchase
2024-09-25

INSIDER TRADES

★
OFFICER: CHIEF FINANCIAL & INFRA. OFCR.
Schilke Tobin
Purchase · 471 shares
2026-08-20
★
DIRECTOR, OFFICER: PRESIDENT & CEO
Struthers Richard Scott
Sale · 5.0K shares
2026-08-07
★
DIRECTOR, OFFICER: PRESIDENT & CEO
Struthers Richard Scott
Sale · 4.4K shares
2026-08-07
★
DIRECTOR, OFFICER: PRESIDENT & CEO
Struthers Richard Scott
Sale · 4.0K shares
2026-08-07

MOST RECENT ANALYST GRADES

GRADE SUMMARY
NEUTRAL 3
HOLD 3
OUTPERFORM 2
MARKET OUTPERFORM 2
OVERWEIGHT 2
IN LINE 1
PERFORM 1
BUY 1
15 GRADES IN THE LAST 12 MONTHS
UBS NEUTRAL TD Cowen HOLD Evercore ISI Group IN LINE Baird OUTPERFORM Cantor Fitzgerald NEUTRAL HC Wainwright & Co. NEUTRAL Jefferies HOLD Jones Trading HOLD

SECTORS PEERS

PEERPRICE
KYMR$118.15COMPARE
PRAX$344.75COMPARE
IMVT$41.20COMPARE
XENE$59.99COMPARE
ACAD$29.11COMPARE
DYN$25.07COMPARE
VKTX$32.16COMPARE
NAMS$25.90COMPARE